These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31119047)

  • 1. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
    Wang Y; Li X; Liu X; Chen Y; Yang C; Tan C; Wang B; Sun Y; Zhang X; Gao Y; Ding J; Meng L
    Cancer Biol Med; 2019 Feb; 16(1):66-83. PubMed ID: 31119047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
    Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
    Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
    Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
    Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors.
    Zhang X; Wang Y; Zhang X; Shen Y; Yang K; Ma Q; Qiao Y; Shi J; Wang Y; Xu L; Yang B; Ge G; Hu L; Kong X; Yang C; Chen Y; Ding J; Meng L
    Signal Transduct Target Ther; 2023 Apr; 8(1):153. PubMed ID: 37041169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
    Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
    Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
    Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.
    Xing H; Gao M; Wang Y; Zhang X; Shi J; Wang X; Liu X; Ma Q; Kong X; Yang C; Ding J; Meng L
    Clin Transl Med; 2022 May; 12(5):e835. PubMed ID: 35604910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
    Wang YX; Zhang X; Ma QY; Hu LD; Zhang X; Wang Y; Xu L; Yang CH; Tan C; Kong XY; Ding J; Meng LH
    Cell Death Dis; 2021 Jan; 12(1):85. PubMed ID: 33446653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer.
    Fan Y; Ding H; Kim D; Bach DH; Hong JY; Xu Y; Lee SK
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.
    Yu X; Liu J; Qiu H; Hao H; Zhu J; Peng S
    Bosn J Basic Med Sci; 2021 Apr; 21(2):198-207. PubMed ID: 32530390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.